Suppr超能文献

给予GM1神经节苷脂可部分抵消大鼠背侧纹状体内与氟哌啶醇治疗相关的形态学变化。

GM1 ganglioside administration partially counteracts the morphological changes associated with haloperidol treatment within the dorsal striatum of the rat.

作者信息

Meshul C K, Stallbaumer R K, Allen C

机构信息

Research Service, VA medical Center, Portland, OR 97201, USA.

出版信息

Psychopharmacology (Berl). 1995 Oct;121(4):461-9. doi: 10.1007/BF02246494.

Abstract

Haloperidol, a typical antipsychotic drug, causes an increase in the mean percentage of synapses within the situation containing a discontinuous, or perforated, postsynaptic density (PSD) following 1 month of treatment (Meshul et al. 1994). This effect is not observed with the atypical antipsychotic drug, clozapine, following subchronic administration (Meshul et al. 1992a). This morphological change is also associated with an increase in the density of dopamine D2 receptors. The synapses containing the perforated PSD are asymmetrical and the nerve terminals contain the neurotransmitter, glutamate, as demonstrated by immunocytochemistry. We have also shown that subchronic treatment with haloperidol (0.5 mg/kg per day, 30 days) results in a decrease in the density of glutamate immunoreactivity within asymmetric nerve terminals associated with perforated and non-perforated PSDs (Meshul and Tan 1994). This could be due to an increase in glutamate release, perhaps due to activation of corticostriatal synapses. Agnati et el. (1983a) reported that administration of GM1 ganglioside blocks the increase in dopamine D2 receptors following haloperidol treatment. GM1 has also been shown to attenuate the release of glutamate (Nicoletti et al. 1989). In order to determine if similar treatment with ganglioside could block the haloperidol-induced ultrastructural changes notes above, rats were co-administered GM1 (10 mg/kg per day) and haloperidol (0.5 mg/kg per day) for 30 days. We report that GM1 blocked the haloperidol-induced increase in striatal asymmetric synapses containing a perforated PSD, but had no effect on the increase in dopamine D2 receptors or the decrease in nerve terminal glutamate immunoreactivity. GM1, either alone or co-administered with haloperidol, also caused a small, but significant, increase in the density of all asymmetric synapses within the striatum. It is possible that the effect of GM1 in attenuating the haloperidol-induced change in glutamate synapses with perforated PSDs is primarily postsynaptic, since GM1 did not block the change in density of glutamate immunoreactivity within asymmetric nerve terminals.

摘要

氟哌啶醇是一种典型的抗精神病药物,在治疗1个月后,会使含有不连续或穿孔突触后致密物(PSD)的突触平均百分比增加(Meshul等人,1994年)。亚慢性给药后,非典型抗精神病药物氯氮平未观察到这种效应(Meshul等人,1992a)。这种形态学变化也与多巴胺D2受体密度的增加有关。含有穿孔PSD的突触是不对称的,免疫细胞化学显示神经末梢含有神经递质谷氨酸。我们还表明,亚慢性给予氟哌啶醇(每天0.5mg/kg,共30天)会导致与穿孔和非穿孔PSD相关的不对称神经末梢内谷氨酸免疫反应性密度降低(Meshul和Tan,1994年)。这可能是由于谷氨酸释放增加,可能是由于皮质纹状体突触的激活。Agnati等人(1983a)报告说,给予GM1神经节苷脂可阻止氟哌啶醇治疗后多巴胺D2受体的增加。GM1还被证明可减弱谷氨酸的释放(Nicoletti等人,1989年)。为了确定类似的神经节苷脂治疗是否能阻断上述氟哌啶醇诱导的超微结构变化,将大鼠联合给予GM1(每天10mg/kg)和氟哌啶醇(每天0.5mg/kg),持续30天。我们报告说,GM1阻断了氟哌啶醇诱导的含有穿孔PSD的纹状体不对称突触的增加,但对多巴胺D2受体的增加或神经末梢谷氨酸免疫反应性的降低没有影响。单独或与氟哌啶醇联合使用的GM1也会使纹状体内所有不对称突触的密度有小幅但显著的增加。GM1减弱氟哌啶醇诱导的穿孔PSD谷氨酸突触变化的作用可能主要是突触后作用,因为GM1没有阻断不对称神经末梢内谷氨酸免疫反应性密度的变化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验